Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
With the approval by the European Commission in November 2012.....
Volgen
Orphan conditions with authorized treatments (at least one per condition) are ordered by prevalence (number of patients per 10,000 in the European Union). Analysis from data on file at the European Medicines Agency (EMA; cut-off: November 2012); in situations where a condition was listed more than once (and with varying prevalence), the lowest prevalence was listed. Ultra-rare conditions (the boxed indications in the figure) were defined as having a prevalence of equal to or less than 0.1 per 10,000 persons in the European Union. Lipoprotein lipase deficiency, targeted by Glybera (alipogene tiparvovec), represents the third rarest disease for which a medical treatment has so far been authorized. The pivotal data submitted for these ultra-rare conditions are listed for comparison in Table 1. ALL, acute lymphoblastic leukaemia; CEL, chronic eosinophilic leukaemia; CFTR, cystic fibrosis transmembrane conductance regulator; HPC, haematopoietic progenitor cell; Ph+, Philadelphia chromosome positive; SGCA, subependymal giant cell astrocytoma. *Treatment in patients who require intrathecal analgesia. ‡With platelet-derived growth factor receptor (PDGR) gene rearrangements. §C1 esterase inhibitor deficiency. Furthermore, surrogate markers for clinical outcome existed for these conditions (Table 1). By contrast, lipoprotein lipase deficiency results in pancreatitis in otherwise often phenotypically healthy individuals — a complication that is not only influenced by various factors including diet, but that also exhibits a much more unpredictable and fluctuating disease course with intermittent healthy periods. Therefore, it would — in theory — be necessary to conduct either a large clinical study enabling for a sufficiently high event rate (which is not feasible for an ultra-rare disease) or a long follow-up in order to detect a sufficient number of events in a smaller patient population (how long would be feasible in a pre-approval situation?). So, to counterbalance the inherent limitations of the clinical database, an approval “under exceptional circumstances”15 with post-approval supplementation of the database was the most appropriate route. The way forward In our view, the message to the scientific community is positive: both committees had complementary approaches. They delivered within the spirit of the legislation and took a scientific approach recognizing the rarity of the disease and the difficulties in obtaining comprehensive data. They acknowledged the evolution of science and considered the data as a whole. It is common in science that in borderline situations two experts can reach different conclusions when balancing certainties and uncertainties. However, this balanced and weighted scientific view of both committees, as briefly highlighted here, resulted in a seemingly 'black and white' outcome, as for a regulatory opinion there are only two possible decisions (positive or negative), and only this was visible to the scientific community.
During the approval procedure the two committees closely collaborated, and they will continue to strengthen their collaboration based on increasing experience. This will be facilitated by the recent inauguration of the EMA Scientific Coordination Board16, which involves all chairpersons of the EMA committees. We do not agree that this is “the perfect bureaucratic response”17, as it is not another committee that complicates procedures but a body that takes a more strategic and coordinative role under the umbrella of the EMA's missions and visions. Its creation is not a consequence of the Glybera procedure, but a logical step towards the fulfilment of the EMA's goal to ensure efficient operation of its core business — principles that were already published in early 2011 (Ref. 18). The role of the CAT was recently challenged6, 7, 8, 9, 10, 11, 12, given that the CHMP is required by legislation to make the final opinion. This may be perceived as though the CAT is not heard, or that it lacks the power to foster innovation and create a fruitful environment for its stakeholders to develop and gain the approval of ATMPs. However, this assumption is not only incorrect but also oversimplified. Besides the fact that the CHMP fully supports innovation, the CAT has considerable influence at the early stage of ATMP development, for example, by systematically reviewing and discussing the CHMP's scientific advice procedures for ATMPs, by participating in the innovation task force meetings concerning ATMPs at the EMA, or when issuing certificates on quality and/or non-clinical data. The approach that the legislator had taken when drafting the ATMP regulation was not intended to separate the licensing procedure for ATMPs from that of other human medicines; it would be difficult to explain to patients why an ATMP should have a different standard compared to a conventional medicine, and it would not be helpful to exclude the CHMP's extensive experience of reviewing dossiers including those for drugs targeting rare diseases. In conclusion, we submit that both committees' deliberations and conclusions illustrate their openness towards innovative approaches to drug development and their willingness to exercise flexibility where scientifically appropriate. The history summarized above also provides a reminder of the regulators' challenge to balance early availability of promising treatments with a need to uphold appropriate standards of evidence, and in borderline situations a different opinion of independent experts can never be fully excluded. We contend that a 'black and white' view of the regulatory procedure for Glybera (or any other similar scenario), as has been expressed in the literature, is not correct; rather, the opinions of the two committees illustrate the shades of grey involved in such procedures and also highlight the shared dedication of the committees to patients and innovation.www.nature.com/nrd/journal/vaop/ncurr...
Leesvoer voor de amerikanen!
@Flosz: Bedankt voor het delen. @Dr. No: Dat zullen ze ook wel doen. Daarnaast kan uniQure nu ook meer data voorleggen.
Allereerst @Flosz, bedankt voor het delen. Nu is mijn Engels wel goed, maar ik vraag het toch liever voor de zekerheid aan jullie. Als ik het goed begrijp, is het onderwerp van discussie, het feit dat Glyberea eerst is afgewezen, en later toch goedgekeurd. De betrokken commissies leggen uit, dat het soms over de nuances gaat, en dat dit een uitzonderlijk geval betreft. Verder meen ik ook te lezen, dat binnen een weliswaar kleine populatie, de resultaten uitzonderlijk positief waren met betrekking tot Glybera. Als mijn Engels ontoereikend is, en mijn conclusie onjuist, dan hoor ik dat graag van jullie.
@BNP: "[..] en dat dit een uitzonderlijk geval betreft" "[..] de resultaten uitzonderlijk positief waren met betrekking tot Glybera." Uitzonderlijk betekent hier niet "geweldig goed" (mocht je dat zo hebben bedoeld) maar de lastige case die AMT heeft voorgelegd. AMT heeft namelijk tijdens de review het onderzoek gewijzigd, door te focussen op een (nieuwe) afhankelijke variabele die het effect van Glybera beter zichtbaar zou maken. Daarbij was die variabele (nog) niet gevalideerd, wat zorgende voor nadere analyse, discussie en onderbouwing. Van de eerste patiënten heeft men geen data van die nieuwe variabele, daarom zagen de commissies graag data van nieuwe patiënten. En dat is lastig omdat de populatie klein is. Alternatief: de huidige patiënten heel lang volgen, maar dat gaat financieel nooit lukken. En wellicht ten koste van patiënten die nooit een oplossing krijgen. Omdat er geen bijwerkingen zijn en de eerste ervaring van patiënten gunstig besluit men goedkeuring te verlenen onder bijzondere omstandigheden. Het is ook een signaal dat de commissies innovatie willen stimuleren in plaats van te blokkeren. uniQure moet met Glybera flink onderzoek (monitoring) blijven doen.
EMA gives details of new 'future-proof' structure The European Medicines Agency (EMA) has started a shake-up of its operating structure as it adapts to the evolving demands of its regulatory function. ….. …. At the time, the EMA noted that a lesson learnt from the Glybera review was that the agency needed to create a more adaptive regulatory framework for new medicines. ..www.pmlive.com/pharma_news/ema_gives_...
Vertaling van een actueel russisch artikel. Wie weet of Van deventer op 11 oktober ergens (en waar) heeft gesproken, hij is namelijk weer wat concreter over Europa (binnenkort) en US (2014. Irina Mamikonyan DE DRUG GLIBERA KOSTPRIJS VAN $ 1.600.000 KAN IN RUSLAND VERSCHIJNEN De drug Glibera kostprijs van $ 1.600.000 kan in Rusland verschijnen De drug wordt reeds goedgekeurd door de EMA en zal binnenkort beschikbaar zijn op de Europese markt. Het bedrijf is ook van plan om het product in de VS, Canada, Brazilië, Mexico, Pakistan, China, Turkije en de GOS-landen te verkopen. UniQuro Nederlandse biotechnologie bedrijf is van plan om de drug in Rusland te commercialiseren voor de behandeling van enzymdeficiëntie lipoproteinazy (LPL) - Glibera (Glybera), meldde 11 oktober de wetenschappelijk directeur van Sandre van Deventer verslaggevers bij het Internationaal Symposium van gen-en mobiele technologieën. De drug wordt reeds goedgekeurd door de EMA en zal binnenkort beschikbaar zijn in de EG. Daarnaast verwacht het bedrijf aan de goedkeuring van de FDA ontvangen en is van plan om de Amerikaanse markt Gliberu in 2014. De kosten van geneesmiddelen (voor eenmalig gebruik) is $ 1.600.000 Enzymdeficientie lipoproteinazy (LPL) wordt gekenmerkt door het feit dat het menselijk lichaam niet optreedt vetmetabolisme, worden opgenomen in het voedsel. De ziekte is een van de wees, en wordt gediagnosticeerd in een of twee personen per 1 miljoen inwoners. Glibera is gebaseerd op adeno-geassocieerd virus (AAV), dat geïntegreerd is in het genoom van LPL-gen. AAV eigenschap is de mogelijkheid om hun genoom integreren in de gastheercel. LPL wordt voornamelijk gesynthetiseerd in het spierweefsel, waardoor een reeks van enkelvoudige intramusculaire injectie van het geneesmiddel in de dij Glibera kan de vervanging van een defect gen op zijn werkkopie, die in feite de drug vervangt de vervormde gen. "Hoewel we niet weten hoe lang het medicijn werkt, maar zeker niet minst 5-7 jaar", - zei Deventer. Volgens hem, de kosten vergelijkbaar met de behandeling van drugs substitutietherapie, maar bij ontvangst een injectie Glibery genoeg. Precies wanneer het geneesmiddel gaat naar de Russische markt - is nog onbekend, maar volgens een topmanager van het Nederlandse bedrijf, heeft uniQuro al een overeenkomst met de Italiaanse Chiesa Farmaceutici SpA, die een kantoor in Moskou heeft ondertekend, op de commercialisering van het geneesmiddel in Rusland, maar ook in Brazilië, Mexico, Pakistan, Turkije, GOS-landen en China. Deventer eerlijk toegegeven dat hij niet weet wie zal betalen voor de behandeling van LPL in Europa en Rusland. "Elk land heeft zijn eigen aanpak. In de meeste gevallen, het betalen, natuurlijk, de overheid "- besloot hij. Foto: pharmafile.com
Sept., 2013. PIP: www.ema.europa.eu/docs/en_GB/document... ************* European Medicines Agency updates on development of its policy on publication and access to clinical-trial datawww.ema.europa.eu/ema/index.jsp?curl=...
From Mutation Identification to Therapy: Discovery and Origins of the First Approved Gene Therapy in the Western Worldonline.liebertpub.com/doi/pdfplus/10....
2.11.1.1. Glybera MAH: UniQure Biopharma B.V. CAT Rapporteur: E. French (EMEA/H/C/002145/II/34) Orphan II/34 Scope: submission of final study report AMT011-02 For information: For adoption: Revised timetable 2.11.2. Other PA Activities 2.11.2.1. Glybera (EMEA/H/C/002145/S/0039), (alipogene tiparvovec), MAH: UniQure Biopharma B.V. Orphan. Second Annual Reassessment For information: Updated Rapporteur’s assessment report For adoption: Draft Opinion CHMP Co-ordinator: G. Markey See also 2.11.2.1. CAT adopted the revised timetable. CAT Rapporteur: E. French CHMP Co-ordinator: G. Markey PRAC Rapporteur: J. Williams CAT adopted by consensus the Draft Opinion of the 2nd Annual assessment of Glybera. Minor changes are introduced in Annex II to update the status of the quality specific obligation (update of the deadline for providing the information on virus safety ).www.ema.europa.eu/docs/en_GB/document... Page4/19
of 3 September 2013 on the acceptance of a modification of an agreed paediatric investigation plan for alipogene tiparvovec (Glybera), (EMEA-000292-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council.. Paediatric investigation plan for alipogene tiparvovec .......... ....... 1. Waiver 1.1. Condition: Treatment of hyperchylomicronaemia The waiver applies to: • The paediatric population from birth to less than 2 years of age; • for solution for injection, for intramuscular use; • on the grounds that the specific medicinal product is likely to be unsafe. 2. Paediatric Investigation Plan 2.1. Condition: Treatment of hyperchylomicronaemia 2.1.1. Indication(s) targeted by the PIP Treatment of lipoprotein lipase deficiency 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development From 2 to less than 18 years of age. 2.1.3. Pharmaceutical form(s) Solution for injection, for intramuscular use 2.1.4. Measures Non- clinical Number of measures:5 Study 1: Pharmacology study of a comparison of the level and persistence of lipoprotein expression in young and mature mice Study 2: Pilot study of biodistribution and germ line transmission in juvenile mice Study 3: Toxicity and biodistribution study in immature mice Study 4: Exploratory toxicity/efficacy study in mice and cynomolgus macaques Study 5: Juvenile toxicity study in mice Clinical Number of measures:2 Study 6: LPLD Registry: observational, multicentre, longitudinal pharmaco-epidemiologic study in lipoprotein lipase-deficient (LPLD) patients, either treated or not treated with alipogene tiparvovec Study 7: Open label, single dose, uncontrolled trial to evaluate safety and efficacy of alipogene tiparvovec in children from 2 to less than 18 years of age diagnosed with lipoprotein lipase deficiency 3. Follow-up, completion and deferral of PIP Concerns on potential long term safety and efficacy issues in relation to paediatric use: Yes Date of completion of the paediatric investigation plan: By December 2021 Deferral for one or more measures contained in the paediatric investigation plan: Yeswww.ema.europa.eu/docs/en_GB/document...
Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies This study has been terminated.(Business reason) March 27, 2015clinicaltrials.gov/ct2/show/NCT01447901
Ter aanvulling post El Gaucho 16-04-2015 21.09u.: www.iex.nl/Forum/Topic/1286603/106/Wa... www.g-ba.de/downloads/39-261-2233/201... German regulator puts UniQure gene therapy appraisal on hold FRANKFURT, April 17 (Reuters) - A German regulator for new drugs has suspended the assessment of the Western world's first gene therapy, UniQure's Glybera, after an adviser to the European drugs watchdog voiced concern over the treatment. Glybera, designed to treat a very rare blood disease, came with a preliminary price tag of 1.1 million euros ($1.2 million), before standard German drug pricing discounts. German body G-BA was due to issue an assessment of the drug's benefits by the end of this month but it said late on Thursday it had decided to miss the legal deadline to get more clarity on the drug's benefits. An adviser for biotech drugs to the European Medicines Agency, a so-called rapporteur, last week said in a report that Glybera, which is marketed by UniQure's unlisted Italian marketing partner Chiesi, lacked efficacy. "Even if the suspension of the procedure violates the legal deadline, the decision is justified and without alternative," G-BA head Josef Hecken said in a statement. "Judging from the statements about the rapporteur's report, his findings must be worrisome." The European Medicines Agency's CHMP committee will consider the rapporteur's report on Glybera at its regular monthly meeting in London next week. The drug has already had a tortuous journey to market as regulators have struggled to assess its effectiveness because of the very small number of patients available for clinical tests. The G-BA's verdict on the drug benefits will play a key role in future negotiations about the reimbursement price between the drug companies and Germany's statutory health insurance funds. Glybera fights a genetic disease called lipoprotein lipase deficiency (LPLD) that clogs the blood with fat. The medicine was approved in Europe two years ago but its launch was delayed to allow for the collection of six-year follow-up data on its benefits. www.reuters.com/article/2015/04/17/he...
EMA/CHMP Agenda of meeting to be held on 20-23 April 2015 Glybera (EMEA/H/C/002145/II/0038), Orphan, (alipogene tiparvovec), MAH: uniQure biopharma B.V., Rapporteur: Elaine French, CHMP Co-ordinator: Greg Markey, “Update of section 5.1 of the SmPC based on the final CSR for Study CT-AMT-011-05, a retrospective clinical records review study undertaken to generate further long- term follow-up data on the incidence and severity of acute pancreatitis episodes in LPLD subjects who previously participated in clinical studies with alipogene tiparvovec or AMT-10.”Request for Supplementary Information adopted on 20.11.2014. • Request for Supplementary information / Opinion : For adoption P.23 www.ema.europa.eu/docs/en_GB/document...
Dus als ik het goed begrijp, dan komt er een verzoek om nadere informatie. Of is dit het voorstel om Glybera toch te accepteren?
Nadere informatie imho. Er zijn ook zaken die besproken worden zonder vermelding in deze "openbare" agenda. Ik weet niet of dit mbt Qure idd. zo is. Uit post 04-04-2015 00:04U. (Minutes 19/20-02-2015). Scope: submission of final study report AMT011-02 For information: For adoption: Revised timetable Second Annual Reasses2.11.1.1. Glybera MAH: UniQure Biopharma B.V. CAT Rapporteur: E. French (EMEA/H/C/002145/II/34) Orphan II/34 Scope: submission of final study report AMT011-02 For information: For adoption: Revised timetable 2.11.2. Other PA Activities 2.11.2.1. Glybera (EMEA/H/C/002145/S/0039), (alipogene tiparvovec), MAH: UniQure Biopharma B.V. Orphan. Second Annual Reassessment For information: Updated Rapporteur’s assessment report For adoption: Draft Opinion CHMP Co-ordinator: G. Markey See also 2.11.2.1. CAT adopted the revised timetable. CAT Rapporteur: E. French CHMP Co-ordinator: G. Markey PRAC Rapporteur: J. Williams CAT adopted by consensus the Draft Opinion of the 2nd Annual assessment of Glybera. Minor changes are introduced in Annex II to update the status of the quality specific obligation (update of the deadline for providing the information on virus safety ).
Publ.d.d. 22-04-2015 Committee for Advanced Therapies (CAT) Agenda for the meeting on 16-17 April 2015 2.11. Type II Variations 2.11.1. Glybera – alipogene tiparvovec; Orphan; EMA/H/C/002145/II/34 UniQure Biopharma B.V.; Scope: submission of final study report CT-AMT—011-02 Rapporteur: E. French; CHMP Coordinators: G. Markey Action: for adoption Document tabled: RSI 2.11.2. Glybera – alipogene tiparvovec; Orphan; EMA/H/C/002145/II/37-G UniQure Biopharma B.V.; Scope: PI update section 4.8 and 5.1 (five years FU of final CSR study 011.01) and FU of 011.3 Rapporteur: E. French; CHMP Coordinators: G. Markey Action: for adoption Document tabled: RSI 2.11.3. Glybera – alipogene tiparvovec; Orphan; EMA/H/C/002145/II/38 UniQure Biopharma B.V.; Scope: PI update section 5.1 (final CSR study 011.05) (FU of 011.03) Rapporteur: E. French; CHMP Coordinators: G. Markey Action: for adoption Document tabled: RSI Presentation on regulatory options www.ema.europa.eu/docs/en_GB/document...
On April 8, 2015, uniQure received a copy of a preliminary assessment report on Glybera prepared by the rapporteur designated by the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA), which is the committee that advises the Committee for Human Medicinal Products (CHMP) on gene therapies. The preliminary report was a response to the Company’s submission to the EMA on September 5, 2014 of a Type II variation, which proposed an amendment to the Glybera Summary of Product Characteristics (SPC) to reflect certain information from the six-year follow up data included in the Company’s final clinical study report. The preliminary assessment report, which represented the sole view of the rapporteur, stated that Glybera lacked efficacy and therefore the benefit-risk balance was negative. The rapporteur’s preliminary report was provided to the CAT for further discussion in advance of the CAT’s monthly meeting on April 16-17. On April 24, the Company received a copy of the final assessment report prepared by the CAT and endorsed by the CHMP, which states the following: “At the April CAT meeting, the CAT discussed the negative rapporteur recommendation on the benefit risk of Glybera. The CAT did not agree with the negative view of the rapporteur and concluded by majority on the following recommendation presented below: The efficacy of Glybera needs to be considered in its totality as defined in the initial approval taking into account, the criteria considered at time of initial approval.” In accordance with the Company’s Type II variation request, the CAT will continue to evaluate the six-year follow up data and has requested supplemental information, which the Company is currently preparing. The Company continues to believe that the clinical data from its Glybera development program, including the six-year follow-up data, support the long-term value and efficacy. However, the Company can provide no assurance regarding the final conclusions of the EMA and G-BA. Any adverse outcomes could require the Company to expend significant additional resources to support its conclusions or could have a material negative impact on the revenue expectations for Glybera. services.corporate-ir.net/SEC/Documen... Een PBtje (d.d.24-04-2015) blijft toch moeilijk.....
Dit is voor Uniqure op dit moment toch de beste uitkomst?
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
887,44
0,00%
EUR/USD
1,0765
+0,00%
FTSE 100
8.213,49
0,00%
Germany40^
18.049,80
+0,27%
Gold spot
2.314,40
+0,55%
NY-Nasdaq Composite
16.156,33
+1,99%
Stijgers
Dalers